{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:39:13Z","timestamp":1790095153937,"version":"4.0.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study evaluates acute toxicities in localized prostate cancer patients undergoing moderately hypofractionated radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Seventy-four patients with biopsy-proven adenocarcinoma prostate who underwent image-guided intensity-modulated radiotherapy were included. Patient characteristics like age, comorbidities, initial PSA, Gleason score, stage, risk grouping, and duration of hormone treatment were captured in a structured format. All patients were treated to a dose of 60 Gy\/20 F over 4 weeks. Acute toxicities were assessed using standardized criteria weekly during radiotherapy and at the 8\n                      <jats:sup>th<\/jats:sup>\n                      and 12\n                      <jats:sup>th<\/jats:sup>\n                      weeks of the start of radiation. Statistical analysis was carried out using descriptive statistics and the Mann\u2013Whitney U test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The genitourinary toxicities peaked at the third week of treatment but decreased by the eighth week. Gastrointestinal toxicities were lesser in incidence which also peaked during weeks 3 and 4 of treatment. Bladder toxicities were more pronounced in diabetic patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value 0.023) and correlated with pretreatment IPSS scores (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value 0.001). Diabetes was a significant predictor of rectal toxicities also (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value 0.003), along with dosimetric parameters (PTV60 volume,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value 0.042; PTV57.6 volume,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value 0.036). However, age, stage, initial PSA, Gleason score, and risk grouping did not significantly impact acute toxicity incidence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Moderately hypofractionated radiotherapy for localized prostate cancer is well tolerated with manageable acute toxicities. Larger trials with more patients and longer follow-ups may be required to confirm the results and evaluate late toxicities and tumor control in our population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_846_24","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:00:37Z","timestamp":1751713237000},"page":"602-605","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Acute toxicity of moderate hypofractionated radiotherapy in localized carcinoma prostate: An observational study"],"prefix":"10.4103","volume":"21","author":[{"given":"Kiran","family":"Paskalice","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagathnath","family":"Krishna Kumarapillai Mohanan Nair","sequence":"additional","affiliation":[{"name":"Div. of Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswin","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis V","family":"James","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"R1-20250707","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"R2-20250707","first-page":"1009","article-title":"Is the ?\/? ratio for prostate tumors really low and does it vary with the level of risk at diagnosis?","volume":"33","author":"Fowler","year":"2013","journal-title":"Anticancer Res"},{"key":"R3-20250707","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JU.0000000000000071","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO and AUA evidence-based guideline","volume":"201","author":"Morgan","year":"2019","journal-title":"J Urol"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11912-017-0584-7","article-title":"The role of hypofractionated radiotherapy in prostate cancer","volume":"19","author":"Benjamin","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"R5-20250707","first-page":"100612","article-title":"Acute and late toxicity patterns of moderate hypo-fractionated radiotherapy for prostate cancer: A systematic review and meta-analysis","volume":"40","author":"Sinzabakira","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomized, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11934-019-0918-0","article-title":"Hypofractionated radiotherapy for localized prostate cancer: When and for whom?","volume":"20","author":"Roy","year":"2019","journal-title":"Curr Urol Rep"},{"key":"R9-20250707","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized Phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"R11-20250707","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/624736","article-title":"Systematic review of the relationship between acute and late gastrointestinal toxicity after radiotherapy for prostate cancer","author":"Peach","year":"2015","journal-title":"Prostate Cancer 2015"},{"key":"R12-20250707","doi-asserted-by":"crossref","first-page":"103432","DOI":"10.1016\/j.critrevonc.2021.103432","article-title":"Toxicity after moderately hypofractionated versus conventionally fractionated prostate radiotherapy: A systematic review and meta-analysis of the current literature","volume":"165","author":"Francolini","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R13-20250707","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/01.CCM.0000170106.61978.D8","article-title":"Acute hyperglycemia and the innate immune system: Clinical, cellular, and molecular aspects","volume":"33","author":"Turina","year":"2005","journal-title":"Crit Care Med"},{"key":"R14-20250707","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0167-8140(02)00060-9","article-title":"Hauer-Jensen The radiotherapeutic injury--A complex \u2018wound\u2019","volume":"63","author":"J. W. Denham","year":"2002","journal-title":"Radiother Oncol"},{"key":"R15-20250707","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2460::AID-CNCR23>3.0.CO;2-N","article-title":"Long-term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma","volume":"85","author":"Zelefsky","year":"1999","journal-title":"Cancer"},{"key":"R16-20250707","first-page":"59","article-title":"What is the impact of diabetes mellitus on radiation-induced acute proctitis after radical radiotherapy for adenocarcinoma prostate? A prospective longitudinal study","volume":"14","author":"Alashkham","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"R17-20250707","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijrobp.2008.04.005","article-title":"Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: Results from a multicentric prospective trial","volume":"73","author":"Arcangeli","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20250707","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ijrobp.2010.03.040","article-title":"External beam radiotherapy for prostate cancer: Urinary outcomes for men with high International Prostate Symptom Scores (IPSS)","volume":"80","author":"Malik","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R19-20250707","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12094-012-0907-y","article-title":"Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer","volume":"15","author":"Lopez","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"R20-20250707","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.meddos.2016.10.002","article-title":"Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy","volume":"42","author":"Arunsingh","year":"2017","journal-title":"Med Dosim"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_846_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:31Z","timestamp":1786647151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_846_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_846_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-05-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}